Q3 2024 |
1,231 |
$6.53B |
+$1.22B |
-$167M |
+$1.05B |
ACIO, DRSK, AAPL, OSCV, MSFT
|
13F-HR |
11/5/2024, 04:33 PM |
Q2 2024 |
1,159 |
$5.23B |
+$873M |
-$253M |
+$620M |
ACIO, DRSK, MSFT, OSCV, AAPL
|
13F-HR |
7/31/2024, 04:55 PM |
Q1 2024 |
1,162 |
$4.66B |
+$1.18B |
-$139M |
+$1.04B |
ACIO, DRSK, OSCV, JUCY, MSFT
|
13F-HR |
5/15/2024, 04:22 PM |
Q4 2023 |
913 |
$3.38B |
+$203M |
-$548M |
-$346M |
ACIO, DRSK, OSCV, AAPL, MSFT
|
13F-HR |
2/13/2024, 02:58 PM |
Q3 2023 |
896 |
$3.42B |
+$679M |
-$564M |
+$115M |
ACIO, DRSK, OSCV, AAPL, DUBS
|
13F-HR |
11/8/2023, 02:33 PM |
Q2 2023 |
781 |
$3.42B |
+$226M |
-$436M |
-$211M |
ACIO, DRSK, OSCV, AAPL, ADME
|
13F-HR |
8/11/2023, 10:13 AM |
Q1 2023 |
785 |
$3.51B |
+$683M |
-$344M |
+$340M |
DRSK, ACIO, ADME, OSCV, IBDT
|
13F-HR |
5/9/2023, 03:19 PM |
Q4 2022 |
791 |
$3.04B |
+$423M |
-$668M |
-$246M |
DRSK, ACIO, IBDS, ADME, IBDT
|
13F-HR |
2/13/2023, 04:13 PM |
Q3 2022 |
761 |
$3.13B |
+$599M |
-$294M |
+$304M |
DRSK, ACIO, ADME, IBDS, BSCP
|
13F-HR |
11/2/2022, 11:49 AM |
Q2 2022 |
650 |
$3B |
+$986M |
-$893M |
+$93.1M |
DRSK, ACIO, IBDS, BSCP, BSCQ
|
13F-HR |
7/29/2022, 02:54 PM |
Q1 2022 |
672 |
$3.25B |
+$681M |
-$250M |
+$430M |
DRSK, IBDQ, IBDO, IBDR, ACIO
|
13F-HR |
5/4/2022, 12:36 PM |
Q4 2021 |
547 |
$2.95B |
+$429M |
-$139M |
+$290M |
DRSK, IBDO, IBDQ, IBDP, ACIO
|
13F-HR |
2/2/2022, 03:03 PM |
Q3 2021 |
519 |
$2.53B |
+$537M |
-$176M |
+$361M |
DRSK, IBDO, IBDN, IBDP, ACIO
|
13F-HR |
10/27/2021, 04:33 PM |
Q2 2021 |
544 |
$2.2B |
+$248M |
-$46.3M |
+$202M |
DRSK, IBDO, ADME, ACIO, IBDN
|
13F-HR |
7/27/2021, 01:18 PM |
Q1 2021 |
497 |
$1.92B |
+$296M |
-$106M |
+$190M |
DRSK, IBDO, ACIO, ADME, IBDN
|
13F-HR |
5/6/2021, 02:38 PM |
Q4 2020 |
453 |
$1.7B |
+$362M |
-$126M |
+$236M |
DRSK, ADME, ACIO, IBDO, IBDN
|
13F-HR |
2/10/2021, 03:12 PM |
Q3 2020 |
440 |
$1.41B |
+$228M |
-$49.1M |
+$179M |
DRSK, ADME, ACIO, IBDO, IBDQ
|
13F-HR |
10/16/2020, 05:40 PM |
Q2 2020 |
396 |
$1.2B |
+$260M |
-$148M |
+$113M |
DRSK, ACIO, ADME, IBDO, IBDQ
|
13F-HR |
7/22/2020, 10:21 AM |
Q1 2020 |
392 |
$979M |
+$348M |
-$260M |
+$88.5M |
DRSK, ACIO, ADME, BSCK, BSCL
|
13F-HR |
5/7/2020, 10:40 AM |
Q4 2019 |
447 |
$983M |
+$271M |
-$191M |
+$80.2M |
DRSK, ACIO, ADME, OSCV, IBDR
|
13F-HR |
2/10/2020, 01:53 PM |
Q3 2019 |
425 |
$876M |
+$281M |
-$116M |
+$165M |
DRSK, ACIO, FTVA, ADME, OSCV
|
Restatement |
11/14/2019, 05:15 PM |
Q2 2019 |
318 |
$704M |
+$166M |
-$56.4M |
+$110M |
DRSK, FTVA, ADME, OSCV, SPDW
|
13F-HR |
8/12/2019, 05:55 PM |
Q1 2019 |
294 |
$579M |
+$303M |
-$122M |
+$182M |
DRSK, FTVA, ADME, OSCV, IBDR
|
13F-HR |
5/15/2019, 04:18 PM |
Q4 2018 |
161 |
$375M |
$0 |
$0 |
|
DRSK, IEF, FTVA, SHY, SPLG
|
13F-HR |
2/12/2019, 03:07 PM |